DOI:
10.1055/s-00000005
Aktuelle Rheumatologie
LinksClose Window
References
Kloppenburg M. et al.
Phase IIa, placebo-controlled, randomised study of lutikizumab, an anti-interleukin-1α and anti-interleukin-1β dual variable domain immunoglobulin, in patients with erosive hand osteoarthritis.
Ann Rheum Dis 2019;
78: 413-420
Access:
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.